Wegovy FAQ UK

Wegovy is a brand of semaglutide used for weight management. It acts on GLP-1 receptors involved in appetite regulation, which can help some people feel fuller, feel less hungry, and reduce food cravings. It is used alongside diet and physical activity, and it should only be supplied after a clinical assessment.

For adults, Wegovy is generally used for weight management in people with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. It is also licensed for some adolescents aged 12 years and above with obesity and body weight above 60kg. Individual providers may apply additional assessment criteria, safety checks, and follow-up requirements.

NHS access is usually through specialist weight-management services and local referral pathways. It is not usually a simple standard GP prescription for weight loss. Eligibility, waiting times, and local service availability can vary.

If you are exploring NHS access, the usual starting point is to ask your GP whether there is a suitable local specialist service and whether referral criteria are met.

Both contain semaglutide, but they are licensed for different uses and supplied in different product formats and dose pathways. Wegovy is the weight-management product. Ozempic is licensed for type 2 diabetes.

The usual weekly titration schedule builds gradually from 0.25mg to 0.5mg, 1mg, 1.7mg, and then 2.4mg. For most adults, 2.4mg weekly is the maintenance dose, or the maximum tolerated dose if 2.4mg is not suitable.

Dose changes should follow prescriber advice, especially if side effects are difficult or treatment has been interrupted.

If a dose is missed, it should usually be taken as soon as possible within 5 days. If more than 5 days have passed, the missed dose is usually skipped and the next dose taken on the normal day.

If more than one dose has been missed, it is sensible to check with the prescriber before restarting, because a lower restart dose may sometimes be advised.

No special branded diet is required, but many people do better with a structured eating pattern. Protein, fibre, hydration, and simpler meal routines often help more than highly restrictive plans that are hard to maintain.

Wegovy can still support weight loss even if exercise is limited, but activity remains useful for fitness, long-term maintenance, and helping preserve muscle mass. A practical starting point for many people is more regular walking plus some form of strength work if appropriate.

Some people notice appetite changes early, but meaningful weight change usually builds over time as the dose is increased gradually. Weekly progress is rarely perfectly linear, so short-term fluctuations are common.

Results vary. In studies, many people lost a clinically meaningful amount of weight when semaglutide was combined with lifestyle support, but individual outcomes depend on starting weight, dose tolerated, adherence, medical history, and whether treatment can be continued long enough to remain effective.

The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, abdominal discomfort, reflux, and reduced appetite. These often appear during treatment initiation or dose increases and may improve with time.

Smaller meals, slower eating, good hydration, and avoiding heavy or very fatty meals around injection day can help some people. If nausea is persistent or worsening, the safest next step is to speak to the prescriber rather than pushing ahead with the next increase.

Urgent medical advice is important if fluids cannot be kept down, dehydration is developing, severe or persistent abdominal pain occurs, or symptoms feel unusually intense or worrying. For emergency symptoms, call 999. For urgent UK advice, NHS 111 is the usual route.

Alcohol is not specifically prohibited for everyone, but it can worsen nausea, reflux, dehydration, and appetite control. Some people find tolerance changes while using GLP-1 medicines, so a cautious approach is sensible.

Some people with type 2 diabetes may use semaglutide, but the correct product, dose, and monitoring plan depend on the wider diabetes treatment picture. This should be managed by the relevant clinician or diabetes team, especially if other glucose-lowering medicines are involved.

Wegovy should not be used during pregnancy and is not recommended while breastfeeding. If pregnancy is planned, semaglutide should usually be stopped at least 2 months beforehand. If pregnancy occurs during treatment, the prescriber should be contacted promptly.

It may be safe if the provider is a properly regulated UK pharmacy or clinic using a real prescribing assessment, identity checks where needed, and a clear complaints process. It is sensible to avoid sellers offering Wegovy without a proper assessment or through informal channels such as social media.

Total cost can vary because the headline figure is not always the full price. Assessment fees, delivery charges, support packages, follow-up reviews, and first-order discounts can all change what is paid in practice.

No. Clinical eligibility should be decided by the prescriber, not by a discount code. Any code simply changes the price if treatment is approved and the provider accepts that code on the relevant order.

It is sensible to compare the final dose-specific price, delivery fees, support level, proof-of-history rules for higher doses, stock position, and whether a provider has any ongoing review requirements before repeat prescribing.

Private providers may use different clinical workflows, identity checks, documentation standards, and follow-up policies. A stricter process does not automatically mean treatment is unavailable. It often reflects the provider’s own prescribing and safety rules.